Target Price | $250.92 |
Price | $200.59 |
Potential |
25.09%
register free of charge
|
Number of Estimates | 18 |
18 Analysts have issued a price target Ascendis Pharma A/S Sponsored ADR 2026 .
The average Ascendis Pharma A/S Sponsored ADR target price is $250.92.
This is
25.09%
register free of charge
$322.35
60.70%
register free of charge
$205.03
2.21%
register free of charge
|
|
A rating was issued by 22 analysts: 21 Analysts recommend Ascendis Pharma A/S Sponsored ADR to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ascendis Pharma A/S Sponsored ADR stock has an average upside potential 2026 of
25.09%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 422.03 | 853.80 |
36.34% | 102.31% | |
EBITDA Margin | -72.67% | -20.21% |
55.06% | 72.19% | |
Net Margin | -103.97% | -22.19% |
42.40% | 78.66% |
17 Analysts have issued a sales forecast Ascendis Pharma A/S Sponsored ADR 2025 . The average Ascendis Pharma A/S Sponsored ADR sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Ascendis Pharma A/S Sponsored ADR EBITDA forecast 2025. The average Ascendis Pharma A/S Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Ascendis Pharma A/S Sponsored ADR Analysts have issued a net profit forecast 2025. The average Ascendis Pharma A/S Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -7.58 | -3.10 |
23.67% | 59.10% | |
P/E | negative | |
EV/Sales | 14.96 |
17 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast for earnings per share. The average Ascendis Pharma A/S Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Ascendis Pharma A/S Sponsored ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
Raymond James |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Analyst Rating | Date |
---|---|
Locked
Raymond James:
Locked
➜
Locked
|
Oct 17 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 13 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 09 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 02 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.